Table 3

Densities of CD14+ cells classified according to HLA-DR expression in tumor intraepithelial and stromal regions and patient survival with inverse probability weighting (IPW)

No. of casesColorectal cancer-specific survivalOverall survival
No. of eventsUnivariable
HR (95% CI)*
Multivariable
HR (95% CI)*†
No. of eventsUnivariable
HR (95% CI)*
Multivariable
HR (95% CI)*†
Tumor intraepithelial region
 CD14+HLA-DR+ cell density
 Q1228941 (referent)1 (referent)1581 (referent)1 (referent)
 Q2228760.88 (0.63 to 1.21)0.90 (0.66 to 1.23)1571.08 (0.82 to 1.43)1.06 (0.81 to 1.40)
 Q3229650.66 (0.47 to 0.94)0.64 (0.45 to 0.93)1610.82 (0.61 to 1.11)0.76 (0.56 to 1.04)
 Q4228480.44 (0.30 to 0.64)0.48 (0.31 to 0.76)1370.64 (0.48 to 0.87)0.61 (0.42 to 0.87)
Ptrend<0.00010.00020.00100.0011
 CD14+HLA-DR cell density
 Q1228591 (referent)1 (referent)1441 (referent)1 (referent)
 Q2228561.04 (0.69 to 1.56)1.00 (0.67 to 1.49)1501.11 (0.82 to 1.51)1.07 (0.78 to 1.48)
 Q3229681.39 (0.95 to 2.05)1.42 (0.97 to 2.09)1481.30 (0.96 to 1.76)1.29 (0.96 to 1.75)
 Q42281002.17 (1.52 to 3.08)1.78 (1.25 to 2.55)1711.84 (1.37 to 2.47)1.59 (1.18 to 2.15)
Ptrend<0.00010.0003<0.00010.0010
Tumor stromal region
 CD14+HLA-DR+ cell density
 Q12281071 (referent)1 (referent)1771 (referent)1 (referent)
 Q2228760.66 (0.48 to 0.91)0.77 (0.56 to 1.06)1540.71 (0.53 to 0.93)0.76 (0.57 to 1.00)
 Q3229580.45 (0.32 to 0.65)0.52 (0.36 to 0.75)1420.57 (0.43 to 0.77)0.59 (0.44 to 0.80)
 Q4228420.33 (0.23 to 0.49)0.42 (0.29 to 0.63)1400.51 (0.38 to 0.67)0.51 (0.38 to 0.69)
Ptrend<0.0001<0.0001<0.0001<0.0001
 CD14+HLA-DR cell density
 Q1228691 (referent)1 (referent)1521 (referent)1 (referent)
 Q2228560.87 (0.59 to 1.28)1.01 (0.69 to 1.48)1441.01 (0.75 to 1.37)1.07 (0.78 to 1.48)
 Q3229821.34 (0.93 to 1.91)1.33 (0.92 to 1.91)1611.35 (1.00 to 1.81)1.35 (0.99 to 1.84)
 Q4228761.10 (0.76 to 1.58)1.24 (0.86 to 1.78)1561.11 (0.82 to 1.49)1.18 (0.86 to 1.62)
Ptrend0.240.120.240.15
  • *IPW was applied to reduce bias due to the availability of tumor tissue after cancer diagnosis (see ’Statistical analysis’ subsection for details).

  • †The multivariable Cox regression model initially included sex, age, year of diagnosis, family history of colorectal cancer, tumor location, tumor differentiation, disease stage, microsatellite instability, CpG island methylator phenotype, KRAS, BRAF, and PIK3CA mutations, and long-interspersed nucleotide element-1 methylation level. A backward elimination with a threshold P of 0.05 was used to select variables for the final models.

  • ‡The Ptrend value was calculated across the ordinal quartiles of each myeloid cell density within tumor epithelial and stromal regions in the IPW-adjusted Cox regression model.